• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MDCO - 216(载脂蛋白A - 米兰/1 - 棕榈酰 - 2 - 油酰 - 磷脂酰胆碱)与人血清共同孵育可增强ABCA1介导的胆固醇流出能力,生成新的前β - 1高密度脂蛋白,并导致高密度脂蛋白大小增加。

Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size.

作者信息

Kempen Herman J, Schranz Dorota B, Asztalos Bela F, Otvos James, Jeyarajah Elias, Drazul-Schrader Denise, Collins Heidi L, Adelman Steven J, Wijngaard Peter L J

机构信息

The Medicines Company (Schweiz) GmbH, Talstrasse 59, 8002 Zürich, Switzerland.

Pacific Biomarkers LLC, 645 Elliott Avenue West, Suite 300, Seattle, WA 98119, USA.

出版信息

J Lipids. 2014;2014:923903. doi: 10.1155/2014/923903. Epub 2014 Nov 12.

DOI:10.1155/2014/923903
PMID:25478232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4244927/
Abstract

MDCO-216 is a complex of dimeric ApoA-IMilano and palmitoyl oleoyl phosphatidylcholine (POPC), previously shown to reduce atherosclerotic plaque burden. Here we studied the effect of incubation of human plasma or serum with MDCO-216 on cholesterol efflux capacity from J774 cells, on prebeta-1 high density lipoprotein (prebeta-1 HDL) and on HDL size assessed by proton nuclear magnetic resonance ((1)H-NMR). MDCO-216 incubated in buffer containing 4% human serum albumin stimulated both ABCA1-mediated efflux and ABCA1-independent cholesterol efflux from J774 macrophages. When incubated with human serum a dose- and time-dependent synergistic increase of the ABCA1-mediated efflux capacity were observed. Using a commercially available ELISA for prebeta-1 HDL, MDCO-216 as such was poorly detected (12-15% of nominal amount of protein). Prebeta-1 HDL was rapidly lost when human plasma alone is incubated at 37°C. In contrast, incubation of human plasma with MDCO-216 at 37°C produced a large amount of new prebeta-1 HDL. Native 2D electrophoresis followed by immunoblotting with an apoA-I antibody, which also detects ApoA-I Milano, confirmed the increase in prebeta-1 HDL upon incubation at 37°C. With the increase of prebeta-1 HDL, the concomitant disappearance of the small alpha-3 and alpha-4 HDL and MDCO-216 and an increase in the large alpha-1 and alpha-2 HDL were observed. Immunoblotting with Mab 17F3 specific for ApoA-I Milano showed the appearance of ApoA-I Milano in alpha-1 and alpha-2, but not in prebeta-1 HDL. (1)H-NMR analysis of plasma incubated with MDCO-216 confirmed rapid disappearance of small-sized HDL particles and increase of medium- and large-sized HDL particles accompanied with a decrease in total HDL particle number. In conclusion, incubation of human plasma or serum with MDCO-216 strongly enhanced ABCA1-mediated cholesterol efflux, caused a strong increase of prebeta-1 HDL, and drastically changed the distribution of HDL subpopulations. Overall, the results are in line with the hypothesis that MDCO-216 fuses with small alpha-migrating HDL particles forming larger particles containing both apoA-I WT and ApoA-I Milano, meanwhile liberating the endogenous wild-type apoA-I which enriches prebeta-1 HDL subpopulation.

摘要

MDCO - 216是二聚体载脂蛋白A - 米兰诺(ApoA - IMilano)与棕榈酰油酰磷脂酰胆碱(POPC)的复合物,此前已证明其可减轻动脉粥样硬化斑块负担。在此,我们研究了用MDCO - 216孵育人血浆或血清对J774细胞胆固醇流出能力、前β - 1高密度脂蛋白(prebeta - 1 HDL)以及通过质子核磁共振((1)H - NMR)评估的HDL大小的影响。在含有4%人血清白蛋白的缓冲液中孵育的MDCOMDCO - 216可刺激J774巨噬细胞的ABCA1介导的流出以及不依赖ABCA1的胆固醇流出。当与人类血清孵育时,观察到ABCA1介导的流出能力呈剂量和时间依赖性协同增加。使用市售的针对prebeta - 1 HDL的ELISA检测,MDCO - 216本身很难被检测到(为蛋白质标称含量的12 - 15%)。当单独将人血浆在37°C孵育时,prebeta - 1 HDL会迅速丢失。相反,在37°C下将人血浆与MDCO - 216孵育会产生大量新的prebeta - 1 HDL。天然二维电泳后用载脂蛋白A - I抗体进行免疫印迹(该抗体也可检测载脂蛋白A - 米兰诺),证实了在37°C孵育后prebeta - 1 HDL增加。随着prebeta - 1 HDL的增加,观察到小的α - 3和α - 4 HDL以及MDCO - 216同时消失,而大的α - 1和α - 2 HDL增加。用对载脂蛋白A - 米兰诺特异的单克隆抗体Mab 17F3进行免疫印迹显示,载脂蛋白A - 米兰诺出现在α - 1和α - 2 HDL中,而不在prebeta - 1 HDL中。对与MDCO - 216孵育的血浆进行(1)H - NMR分析证实,小尺寸HDL颗粒迅速消失,中尺寸和大尺寸HDL颗粒增加,同时HDL颗粒总数减少。总之,用人血浆或血清与MDCO - 216孵育可强烈增强ABCA1介导的胆固醇流出,导致prebeta - 1 HDL大幅增加,并显著改变HDL亚群的分布。总体而言,这些结果符合以下假设:MDCO - 216与小的α迁移HDL颗粒融合形成同时含有载脂蛋白A - I野生型(apoA - I WT)和载脂蛋白A - 米兰诺的更大颗粒,同时释放内源性野生型载脂蛋白A - I,从而使prebeta - 1 HDL亚群富集。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1613/4244927/20e5e299e4d0/JL2014-923903.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1613/4244927/cd4fe4a3e449/JL2014-923903.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1613/4244927/8c129b78c809/JL2014-923903.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1613/4244927/a1da0c837fb5/JL2014-923903.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1613/4244927/20e5e299e4d0/JL2014-923903.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1613/4244927/cd4fe4a3e449/JL2014-923903.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1613/4244927/8c129b78c809/JL2014-923903.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1613/4244927/a1da0c837fb5/JL2014-923903.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1613/4244927/20e5e299e4d0/JL2014-923903.004.jpg

相似文献

1
Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size.MDCO - 216(载脂蛋白A - 米兰/1 - 棕榈酰 - 2 - 油酰 - 磷脂酰胆碱)与人血清共同孵育可增强ABCA1介导的胆固醇流出能力,生成新的前β - 1高密度脂蛋白,并导致高密度脂蛋白大小增加。
J Lipids. 2014;2014:923903. doi: 10.1155/2014/923903. Epub 2014 Nov 12.
2
High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.健康志愿者和稳定型冠状动脉疾病患者输注MDCO-216(载脂蛋白A-米兰/棕榈酰油酰磷脂酰胆碱)后的高密度脂蛋白亚组分及胆固醇流出能力
Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):736-42. doi: 10.1161/ATVBAHA.115.307052. Epub 2016 Feb 25.
3
A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease.单次输注 MDCO-216(ApoA-1 Milano/POPC)可增加健康志愿者和稳定型冠状动脉疾病患者的 ABCA1 介导的胆固醇流出和前β1 高密度脂蛋白。
Eur Heart J Cardiovasc Pharmacother. 2016 Jan;2(1):23-9. doi: 10.1093/ehjcvp/pvv041. Epub 2015 Dec 11.
4
Structural modification of plasma HDL by phospholipids promotes efficient ABCA1-mediated cholesterol release.磷脂对血浆高密度脂蛋白的结构修饰促进了ABCA1介导的胆固醇有效释放。
J Lipid Res. 2005 Jul;46(7):1457-65. doi: 10.1194/jlr.M400477-JLR200. Epub 2005 Jan 16.
5
Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.重复给予载脂蛋白 A-I Milano/POPC 对食蟹猴血脂、载脂蛋白和血清胆固醇流出能力的影响。
J Lipid Res. 2013 Sep;54(9):2341-53. doi: 10.1194/jlr.M033779. Epub 2013 Jul 4.
6
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.载脂蛋白 A-I 输注治疗急性冠状动脉综合征:过去、现在和未来。
Curr Atheroscler Rep. 2022 Jul;24(7):585-597. doi: 10.1007/s11883-022-01025-7. Epub 2022 May 7.
7
Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients.在健康志愿者和稳定型冠状动脉疾病患者中单次输注递增剂量的MDCO-216(载脂蛋白A-米兰/1-棕榈酰-2-油酰磷脂酰胆碱)后脂蛋白脂质的持续变化。
Atherosclerosis. 2016 Dec;255:17-24. doi: 10.1016/j.atherosclerosis.2016.10.042. Epub 2016 Oct 24.
8
A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux.一种含有载脂蛋白A-I(米兰)二聚体的独特的蛋白酶敏感型高密度脂蛋白颗粒可有效促进ATP结合盒转运体A1介导的细胞胆固醇外流。
J Biol Chem. 2007 Feb 23;282(8):5125-32. doi: 10.1074/jbc.M609336200. Epub 2006 Dec 12.
9
High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk.高密度脂蛋白颗粒、细胞胆固醇外流与冠心病风险
Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):2007-2015. doi: 10.1161/ATVBAHA.118.311117.
10
High density lipoprotein particle size restriction in apolipoprotein A-I(Milano) transgenic mice.载脂蛋白A-I(米兰)转基因小鼠中高密度脂蛋白颗粒大小的限制
J Lipid Res. 1997 Nov;38(11):2314-21.

引用本文的文献

1
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction.CSL112(载脂蛋白 A-I [人])预防心肌梗死患者主要不良心血管事件的生物学基础和作用机制。
Eur Heart J Cardiovasc Pharmacother. 2023 Jun 2;9(4):387-398. doi: 10.1093/ehjcvp/pvad014.
2
Nascent HDL (High-Density Lipoprotein) Discs Carry Cholesterol to HDL Spheres: Effects of HDL Particle Remodeling on Cholesterol Efflux.新生的高密度脂蛋白(HDL)盘携带胆固醇至 HDL 球体:HDL 颗粒重塑对胆固醇流出的影响。
Arterioscler Thromb Vasc Biol. 2020 May;40(5):1182-1194. doi: 10.1161/ATVBAHA.120.313906. Epub 2020 Mar 5.
3

本文引用的文献

1
Evidence for the presence of lipid-free monomolecular apolipoprotein A-1 in plasma.血浆中存在无脂单分子载脂蛋白 A-1 的证据。
J Lipid Res. 2014 Feb;55(2):214-25. doi: 10.1194/jlr.M041038. Epub 2013 Dec 4.
2
Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.贝特类药物和烟酸缓释剂对血脂异常患者高密度脂蛋白颗粒大小分布和胆固醇流出能力的影响差异。
J Clin Lipidol. 2013 Sep-Oct;7(5):414-22. doi: 10.1016/j.jacl.2013.06.007. Epub 2013 Jun 27.
3
Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.
Roles of Reconstituted High-Density Lipoprotein Nanoparticles in Cardiovascular Disease: A New Paradigm for Drug Discovery.
载脂蛋白组装的高密度脂蛋白纳米颗粒在心血管疾病中的作用:药物发现的新模式。
Int J Mol Sci. 2020 Jan 23;21(3):739. doi: 10.3390/ijms21030739.
4
Successful treatment of established heart failure in mice with recombinant HDL (Milano).采用重组高密度脂蛋白(Milano)成功治疗已建立的心力衰竭小鼠模型。
Br J Pharmacol. 2018 Nov;175(21):4167-4182. doi: 10.1111/bph.14463. Epub 2018 Sep 19.
5
Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio.载脂蛋白 A-I 降低动脉粥样硬化进展的机制:动员微区胆固醇和减少 CD131 表达细胞的数量
J Am Heart Assoc. 2016 Nov 7;5(11):e004401. doi: 10.1161/JAHA.116.004401.
6
Translational and Therapeutic Approaches to the Understanding and Treatment of Dyslipidemia.血脂异常的理解与治疗的转化及治疗方法
Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):e56-61. doi: 10.1161/ATVBAHA.116.307808.
7
High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.高密度脂蛋白:天然的多功能纳米颗粒。
ACS Nano. 2016 Mar 22;10(3):3015-41. doi: 10.1021/acsnano.5b07522. Epub 2016 Feb 25.
8
ApoA-I-Directed Therapies for the Management of Atherosclerosis.用于动脉粥样硬化管理的载脂蛋白A-I导向疗法。
Curr Atheroscler Rep. 2015 Oct;17(10):60. doi: 10.1007/s11883-015-0539-0.
新型重组成分高密度脂蛋白(CSL112)显著增强 ABCA1 依赖性胆固醇流出。
Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2202-11. doi: 10.1161/ATVBAHA.113.301981. Epub 2013 Jul 18.
4
Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.重复给予载脂蛋白 A-I Milano/POPC 对食蟹猴血脂、载脂蛋白和血清胆固醇流出能力的影响。
J Lipid Res. 2013 Sep;54(9):2341-53. doi: 10.1194/jlr.M033779. Epub 2013 Jul 4.
5
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.在血脂异常患者中,达塞曲匹联合普伐他汀对脂蛋白代谢及高密度脂蛋白组成和功能的影响:一项 IIb 期剂量范围研究的结果。
Am Heart J. 2012 Mar;163(3):515-21, 521.e1-3. doi: 10.1016/j.ahj.2011.11.017.
6
An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice.载脂蛋白 A-I 模拟肽生成 HDL 样颗粒并增加小鼠的 α-1 高密度脂蛋白亚组分。
J Lipid Res. 2012 Apr;53(4):643-52. doi: 10.1194/jlr.M020438. Epub 2012 Jan 27.
7
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events.高密度脂蛋白(HDL)的检测、颗粒异质性、建议的命名法,以及与动脉粥样硬化性心血管事件的关系。
Clin Chem. 2011 Mar;57(3):392-410. doi: 10.1373/clinchem.2010.155333. Epub 2011 Jan 25.
8
Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size.梯度凝胶电泳与核磁共振光谱法在估计 LDL 和 HDL 颗粒大小与冠心病风险相关性中的比较。
Clin Chem. 2010 May;56(5):789-98. doi: 10.1373/clinchem.2009.140939. Epub 2010 Mar 26.
9
Integrated solution to purification challenges in the manufacture of a soluble recombinant protein in E. coli.大肠杆菌中可溶性重组蛋白生产中纯化挑战的综合解决方案。
Biotechnol Bioeng. 2010 Feb 1;105(2):239-49. doi: 10.1002/bit.22542.
10
High-density lipoprotein particle size and concentration and coronary risk.高密度脂蛋白颗粒大小、浓度与冠心病风险
Ann Intern Med. 2009 Jan 20;150(2):84-93. doi: 10.7326/0003-4819-150-2-200901200-00006.